Thinking of joining a study?

Register your interest

NCT05590637 | RECRUITING | Parkinson's Disease Psychosis


Comparing Antipsychotic Medications in LBD Over Time
Sponsor:

The University of Texas Health Science Center at San Antonio

Brief Summary:

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

Condition or disease

Parkinson's Disease Psychosis

Dementia With Lewy Bodies

Intervention/treatment

Pimavanserin

Quetiapine

Phase

PHASE4

Detailed Description:

Psychosis (hallucinations and delusions) is a common problem in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). PD is a common neurodegenerative disorder that causes movement, cognitive, and psychiatric symptoms. DLB is a similar disorder, though causes more severe cognitive and psychiatric problems. Psychosis is highly prevalent among people with PD and DLB, often manifesting as visual hallucinations or paranoid delusions. Up to 60% of people with PD will experience psychosis over the course of their disease. Psychosis is associated with increased mortality, caregiver burden, and poorer quality of life. More study is needed to determine the best way to treat psychosis in PD and DLB. Currently, both quetiapine and pimavanserin are used in clinical practice for psychosis in PD and DLB. However, few comparison studies have been done and it is unclear if one medication is superior to the other. This will be a clinical trial comparing quetiapine and pimavanserin among patients with psychosis due to PD or DLB requiring initiation of a medication. Patients will be randomized to quetiapine or pimavanserin and improvement in psychosis at 6 months will be compared between the groups.

Study Type : INTERVENTIONAL
Estimated Enrollment : 94 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease
Actual Study Start Date : 2022-04-22
Estimated Primary Completion Date : 2026-08
Estimated Study Completion Date : 2027-02

Information not available for Arms and Intervention/treatment

Ages Eligible for Study:
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Patients seen in the neurology clinic at UT Health San Antonio
  • * Diagnosed with psychosis due to PD or DLB
  • * Requiring initiation of an antipsychotic medication
  • * Clinical equipoise between quetiapine and pimavanserin must exist
  • * The prescribing provider must be comfortable prescribing and managing both quetiapine and pimavanserin
Exclusion Criteria
  • * Medical contraindication to either medication
  • * Caregiver unavailable to complete NPI-Q
  • * Currently taking an antipsychotic medication
  • * Prescribing provider unwilling to manage either medication

Comparing Antipsychotic Medications in LBD Over Time

Location Details

NCT05590637


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


RECRUITING

United States, Texas

University Health System

Saint Anthony, Texas, United States, 78229

RECRUITING

United States, Texas

UT Health Science Center - San Antonio

Saint Anthony, Texas, United States, 78229

Loading...